Is ADMA Biologics Inc (ADMA) undervalued? · P/E 22, rev $426.5M
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
This page asks whether ADMA Biologics Inc (ADMA) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ADMA 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ADMA to the stock page model before you treat a low multiple as a gift.
Not investment advice.